Document:

EX-10.7

 Exhibit 10.7 

PLIANT THERAPEUTICS, INC. 

EXECUTIVE SEVERANCE PLAN 

1. Purpose. Pliant Therapeutics, Inc., a Delaware corporation (the “Company”) considers it essential to the best interests of
its stockholders to foster the continuous employment of key management personnel. The Board of Directors of the Company (the “Board”) recognizes, however, that, as is the case with many publicly-held corporations, the possibility of an
involuntary termination of employment, either before or after a Change in Control (as defined in Section 2 hereof), exists and that such possibility, and the uncertainty and questions that it may raise among management, may result in the
departure or distraction of management personnel to the detriment of the Company and its stockholders. Therefore, the Board has determined that the Pliant Therapeutics, Inc. Executive Severance Plan (the “Plan”) should be adopted to
reinforce and encourage the continued attention and dedication of the Company’s Covered Executives (as defined in Section 2 hereof) to their assigned duties without distraction. Nothing in this Plan shall be construed as creating an
express or implied contract of employment and nothing shall alter the “at will” nature of the Covered Executives’ employment with the Company. 

2. Definitions. The following terms shall be defined as set forth below: 

(a) “Accounting Firm” shall mean a nationally recognized accounting firm selected by the Company. 

(b) “Administrator” means the Board or the Compensation Committee of the Board. 

(c) “Base Salary” shall mean the higher of (i) the annual base salary in effect immediately prior to the Date of
Termination or (ii) the annual base salary in effect for the year immediately prior to the year in which the Date of Termination occurs. 

(d) “Cause” shall mean, and shall be limited to, the occurrence of any one or more of the following events: 

(i) the Covered Executive’s unauthorized use or disclosure of the Company’s confidential information or trade
secrets; 
 (ii) the Covered Executive’s material breach of any agreement between the Covered Executive and the Company;

 (iii) the Covered Executive’s material failure to comply with the Company’s written policies or rules; 

(iv) the Covered Executive’s gross negligence or willful misconduct in connection with the Covered Executive’s
performance of his/her duties to the Company; 

  
 1 

 (v) the Covered Executive’s continuing failure to perform assigned
duties after receiving written notification of the failure from the Company and, if curable, a period of thirty (30) days to cure such failure; 

(vi) the conviction of, indictment for or plea of nolo contendere by the Covered Executive to a felony or a crime involving
moral turpitude; or 
 (vii) the Covered Executive’s failure to cooperate in good faith with a governmental or internal
investigation of the Company or its directors, officers or employees, if the Company has requested the Covered Executive’s cooperation. 

(e) “Change in Control” shall mean a Sale Event, as defined in the Pliant Therapeutics, Inc. 2020 Stock Option and Incentive
Plan, as amended from time to time. 
 (f) “Change in Control Period” shall mean the period beginning on the date of a
Change in Control and ending on the one-year anniversary of the Change in Control. 
 (g)
“Code” shall mean the Internal Revenue Code of 1986, as amended. 
 (h) “Covered Executives” shall mean
Tier 1 Executive and those other employees designated by the Administrator in its sole discretion as the Tier 2 Executives, and, in each case, who meet the eligibility requirements set forth in Section 4 of the Plan. 

(i) “Date of Termination” shall mean the date that a Covered Executive’s employment with the Company (or any successor)
ends, which date shall be specified in the Notice of Termination. Notwithstanding the foregoing, a Covered Executive’s employment shall not be deemed to have been terminated solely as a result of the Covered Executive becoming an employee of
any direct or indirect successor to the business or assets of the Company. 
 (j) “Disability” shall mean the following: if
through any illness, injury, accident or condition of either a physical or psychological nature, the Covered Executive becomes unable to perform substantially all of his duties and responsibilities for a continuous period of sixteen
(16) consecutive weeks or for any twenty-six (26) weeks within a fifty-two (52) week period.
Determinations as to whether Covered Executive is Disabled shall be made by a physician selected by the Board or its insurers and acceptable to the Covered Executive or the Covered Executive’s legal representative, such agreement as to
acceptability not to be unreasonably withheld or delayed. 
 (k) “Good Reason” shall mean that the Covered Executive has
complied with the “Good Reason Process” following the occurrence of any of the following events: 
 (i) a material
diminution in the Covered Executive’s annual base salary other than across the board decreases in annual base salary similarly affecting all executives of the Company; 

(ii) the Company requiring the Covered Executive to relocate (other than for travel incident to the Covered Executive’s
performance of his or her duties on behalf of the Company) a distance of more than fifty (50) miles from the Covered Executive’s current principal place of business; or 

  
 2 

 (iii) any material diminution in the Covered Executive’s position,
responsibilities, authority or duties. 
 For purposes of Section 2(k)(iii), a change in the reporting relationship, or a change in a title will not,
by itself, be sufficient to constitute a material diminution of responsibilities, authority or duty. 
 (l) “Good Reason
Process” shall mean: 
 (i) the Covered Executive reasonably determines in good faith that a “Good Reason”
condition has occurred; 
 (ii) the Covered Executive notifies the Company in writing of the first occurrence of the Good
Reason condition within sixty (60) days of the first occurrence of such condition; 
 (iii) the Covered Executive
cooperates in good faith with the Company’s efforts, for a period of not less than thirty (30) days following such notice (the “Cure Period”), to remedy the condition; 

(iv) notwithstanding such efforts, the Good Reason condition continues to exist following the Cure Period; and 

(v) the Covered Executive terminates his or her employment and provides the Company with a Notice of Termination with respect
to such termination, each within sixty (60) days after the end of the Cure Period. 
 If the Company cures the Good Reason condition
during the Cure Period, Good Reason shall be deemed not to have occurred. 
 (m) “Notice of Termination” shall mean a
written notice which shall indicate the specific termination provision in this Plan relied upon for the termination of a Covered Executive’s employment and the Date of Termination. 

(n) “Participation Agreement” shall mean an agreement between a Covered Executive and the Company that
acknowledges the Covered Executive’s participation in the Plan.  
 (o) “Qualified Termination
Event” shall mean (i) a termination of the Covered Executive’s employment by the Company other than for Cause, death or Disability or (ii) the Covered Executive’s resignation from the Company for Good Reason. 

(p) “Restrictive Covenants Agreement” shall mean the Employee Confidential Information and Inventions Assignment Agreement or
similar agreement entered into between the Covered Executive and the Company. 
 (q) “Tier 1 Executive” shall mean the
Company’s Chief Executive Officer. 

  
 3 

 (r) “Tier 2 Executives” shall mean the individuals designated as such by
the Administrator and who are listed in Exhibit A, attached hereto, as such exhibit is amended by the Administrator from time to time. 

3. Administration of the Plan.  

(a) Administrator. The Plan shall be administered by the Administrator. 

(b) Powers of Administrator. The Administrator shall have all powers necessary to enable it properly to carry out its duties with
respect to the complete control of the administration of the Plan. Not in limitation, but in amplification of the foregoing, the Administrator shall have the power and authority in its discretion to: 

(i) construe the Plan to determine all questions that shall arise as to interpretations of the Plan’s provisions; 

(ii) determine which individuals are and are not Covered Executives, designate an individual as a Tier 2 Executive, determine
the benefits to which any Covered Executives may be entitled, the eligibility requirements for participation in the Plan and all other matters pertaining to the Plan; 

(iii) adopt amendments to the Plan which are deemed necessary or desirable to comply with all applicable laws and regulations,
including but not limited to Code Section 409A and the guidance thereunder; 
 (iv) make all determinations it deems
advisable for the administration of the Plan, including the authority and ability to delegate administrative functions to a third party; 

(v) decide all disputes arising in connection with the Plan; and 

(vi) otherwise supervise the administration of the Plan. 

(c) All decisions and interpretations of the Administrator shall be binding on all persons, including the Company and Covered Executives. 

4. Eligibility. All Covered Executives who have executed and submitted to the Company a Participation Agreement, and satisfied such
other requirements as may be determined by the Administrator, are eligible to participate in the Plan. The Administrator may determine at any time that a Covered Executive should no longer be designated as such as a result of a material change in
such Covered Executive’s role, and such individual shall cease to be eligible to participate in the Plan upon the Administrator taking action by resolution to update the applicable Exhibit hereto. 

5. Termination Benefits Generally. In the event a Covered Executive’s employment with the Company is terminated for any reason, the
Company shall pay or provide to the Covered Executive any earned but unpaid salary, unpaid expense reimbursements in accordance with Company policy, accrued but unused vacation or leave entitlement, and any vested benefits the Covered Executive may
have under any employee benefit plan of the Company in accordance with the terms and conditions of such employee benefit plan (collectively, the “Accrued Benefits”), within the time required by law but in no event more than sixty
(60) days after the Date of Termination. 

  
 4 

 6. Termination Not in Connection with a Change in Control. In the event of a
termination of the Covered Executive’s employment by the Company, other than for Cause, death or Disability, at any time other than during the Change in Control Period, with respect to such Covered Executive, in addition to the Accrued
Benefits, subject to his or her execution of a separation agreement in a form and manner satisfactory to the Company containing, among other provisions, a general release of claims in favor of the Company and related persons and entities,
confidentiality, return of property, and non-disparagement provisions and reaffirmation of the Restrictive Covenants Agreement (the “Separation Agreement and Release”) and the Separation Agreement
and Release becoming irrevocable, all within the time period set forth in the Separation Agreement and Release but in no event more than sixty (60) days after the Date of Termination, and subject to the Covered Executive complying with the
Separation Agreement and Release, the Company shall: 
 (a) pay the Covered Executive an amount equal to the sum of (i) twelve (12)
months’ Base Salary for the Tier 1 Executive and nine (9) months’ Base Salary for each Tier 2 Executive (ii) plus the Covered Executive’s annual target bonus in effect immediately prior to the Date of Termination, prorated
as of the Covered Executive’s Date of Termination; and 
 (b) if the Covered Executive was participating in the Company’s group
health plan immediately prior to the Date of Termination and elects COBRA health continuation, then the Company shall pay to the Covered Executive a monthly cash payment in an amount equal to the monthly employer contribution that the Company would
have made to provide health insurance to the Covered Executive if the Covered Executive had remained employed by the Company, based on the premiums as of the Date of Termination, until the earlier of (i) twelve (12) months for the Tier 1
Executive and nine (9) months for each Tier 2 Executive after the Date of Termination or (ii) the date on which the Covered Executive obtains other employment. 

The amounts payable under Section 6(a) and (b), as applicable, shall be paid out in substantially equal installments in accordance with the
Company’s payroll practice over twelve (12) months for the Tier 1 Executive and over nine (9) months for each Tier 2 Executive within sixty (60) days after the Date of Termination; provided, however, that if the 60-day period begins in one calendar year and ends in a second calendar year, the amounts shall be paid in the second calendar year no later than the last day of such 60-day
period; provided further, that the initial payment shall include a catch-up payment to cover amounts retroactive to the day immediately following the Date of Termination. Each payment pursuant to this Plan is
intended to constitute a separate payment for purposes of Treasury Regulation Section 1.409A-2(b)(2). 

7. Termination in Connection with a Change in Control. In the event a Qualified Termination Event occurs within the Change in Control
Period, then with respect to such Covered Executive, in addition to the Accrued Benefits, subject to his or her execution and non-revocation of the Separation Agreement and Release, all within the time period
set forth in the Separation Agreement and Release, but in no event more than sixty (60) days after the Date of Termination, the Company shall: 

  
 5 

 (a) cause 100% of the outstanding and unvested equity awards with time-based vesting held by
the Covered Executive to immediately become fully vested, exercisable or nonforfeitable as of the Date of Termination; provided, that the performance conditions applicable to any outstanding and unvested equity awards subject to performance
conditions will be deemed satisfied at the target level specified in the terms of the applicable award agreement. Notwithstanding the foregoing, in the event of a Change in Control where the
parties to such Change in Control do not provide for the assumption, continuation or substitution of equity awards of the Company, any and all outstanding and unvested equity awards held by the Covered Executive shall be subject to Section 3(d)
of the Company’s 2020 Stock Option and Incentive Plan, as amended from time to time; 
 (b) pay to the Covered Executive an amount equal
to the sum of (i) 150% of Base Salary for the Tier 1 Executive and 100% of Base Salary for each Tier 2 Executive plus (ii) 150% for the Tier 1 Executive and 100% for each Tier 2 Executive, of the Covered Executive’s annual target bonus in
effect immediately prior to the Qualified Termination Event (or the Covered Executive’s target bonus in effect immediately prior to the Change in Control, if higher); and 

(c) if the Covered Executive was participating in the Company’s group health plan immediately prior to the Date of Termination and elects
COBRA health continuation, then the Company shall pay to the Covered Executive a lump sum cash payment in an amount equal to the monthly employer contribution that the Company would have made to provide health insurance to the Covered Executive if
the Covered Executive had remained employed by the Company for eighteen (18) months for the Tier 1 Executive and twelve (12) months for each Tier 2 Executive after the Date of Termination, based on the premiums as of the Date of
Termination. 
 The amounts payable under Section 7(b) and (c), as applicable, shall be paid out in a lump sum within sixty (60) days after the
Date of Termination; provided, however, that if the 60-day period begins in one calendar year and ends in a second calendar year, the amounts shall be paid in the second calendar year no later than the last
day of the 60-day period. For the avoidance of doubt, the severance pay and benefits provided in this Section 7 shall apply in lieu of, and expressly supersede, the provisions of Section 6 and no
Covered Executive shall be entitled to the severance pay and benefits under both Section 6 and 7 hereof. 
 8. Additional
Limitation. 
 (a) Anything in this Plan to the contrary notwithstanding, in the event that the amount of any compensation, payment or
distribution by the Company to or for the benefit of the Covered Executive, whether paid or payable or distributed or distributable pursuant to the terms of this Plan or otherwise, calculated in a manner consistent with Section 280G of the Code
and the applicable regulations thereunder (the “Aggregate Payments”), would be subject to the excise tax imposed by Section 4999 of the Code, then the Aggregate Payments shall be reduced (but not below zero) so that the sum of all of
the Aggregate Payments shall be $1.00 less than the amount at which the Covered Executive becomes subject to the excise tax imposed by Section 4999 of 

  
 6 

 
the Code; provided that such reduction shall only occur if it would result in the Covered Executive receiving a higher After Tax Amount (as defined below) than the Covered Executive would receive
if the Aggregate Payments were not subject to such reduction. In the event of such reduction, the Aggregate Payments shall be reduced in the following order, in each case, in reverse chronological order beginning with the Aggregate Payments that are
to be paid the furthest in time from consummation of the transaction that is subject to Section 280G of the Code: (i) cash payments not subject to Section 409A of the Code; (ii) cash payments subject to Section 409A of the
Code; (iii) equity-based payments and acceleration; and (iv) non-cash forms of benefits; provided that in the case of all the foregoing Aggregate Payments all amounts or payments that are not subject
to calculation under Treas. Reg. §1.280G-1, Q&A-24(b) or (c) shall be reduced before any amounts that are subject to calculation under Treas. Reg. §1.280G-1, Q&A-24(b) or (c). 
 (b) For purposes of this
Section 8, the “After Tax Amount” means the amount of the Aggregate Payments less all federal, state, and local income, excise and employment taxes imposed on the Covered Executive as a result of the Covered Executive’s receipt
of the Aggregate Payments. For purposes of determining the After Tax Amount, the Covered Executive shall be deemed to pay federal income taxes at the highest marginal rate of federal income taxation applicable to individuals for the calendar year in
which the determination is to be made, and state and local income taxes at the highest marginal rates of individual taxation in each applicable state and locality, net of the maximum reduction in federal income taxes (if any) which could be obtained
from deduction of such state and local taxes. 
 (c) The determination as to whether a reduction in the Aggregate Payments shall be made
pursuant to Section 8(a) shall be made by the Accounting Firm, which shall provide detailed supporting calculations both to the Company and the Covered Executive within fifteen (15) business days of the Date of Termination, if applicable,
or at such earlier time as is reasonably requested by the Company or the Covered Executive. Any determination by the Accounting Firm shall be binding upon the Company and the Covered Executive. 

9. Restrictive Covenants Agreement. 
 As a
condition to participating in the Plan, each Covered Executive shall continue to comply with the terms and conditions contained in the Restrictive Covenants Agreements or similar agreement entered into between the Covered Executive and the Company
and such other agreement(s) as designated in the applicable Participation Agreement. If a Covered Executive has not entered into a Restrictive Covenants Agreement or similar agreement with the Company, he or she shall enter into such agreement prior
to participating in the Plan.  
 10. Withholding. All payments made by the
Company under this Plan shall be subject to any tax or other amounts required to be withheld by the Company under applicable law. 

  
 7 

 11. Section 409A. 

(a) Anything in this Plan to the contrary notwithstanding, if at the time of the Covered Executive’s “separation from service”
within the meaning of Section 409A of the Code, the Company determines that the Covered Executive is a “specified employee” within the meaning of Section 409A(a)(2)(B)(i) of the Code, then to the extent any payment or benefit
that the Covered Executive becomes entitled to under this Plan would be considered deferred compensation subject to the twenty (20) percent additional tax imposed pursuant to Section 409A(a) of the Code as a result of the application of
Section 409A(a)(2)(B)(i) of the Code, such payment shall not be payable and such benefit shall not be provided until the date that is the earlier of (i) six (6) months and one (1) day after the Covered Executive’s separation from
service, or (ii) the Covered Executive’s death. If any such delayed cash payment is otherwise payable on an installment basis, the first payment shall include a catch-up payment covering amounts that
would otherwise have been paid during the six-month period but for the application of this provision, and the balance of the installments shall be payable in accordance with their original schedule. 

(b) The parties intend that this Plan will be administered in accordance with Section 409A of the Code and that all amounts payable
hereunder shall be exempt from the requirements of such section as a result of being “short term deferrals” for purposes of Section 409A of the Code to the greatest extent possible. To the extent that any provision of this Plan is not
exempt from Section 409A of the Code and ambiguous as to its compliance with Section 409A of the Code, the provision shall be read in such a manner to comply with Section 409A of the Code. Each payment pursuant to this Plan is
intended to constitute a separate payment for purposes of Treasury Regulation Section 1.409A-2(b)(2). The parties agree that this Plan may be amended, as reasonably requested by either party, and as may
be necessary to fully comply with Section 409A of the Code and all related rules and regulations in order to preserve the payments and benefits provided hereunder without additional cost to either party. 

(c) To the extent that any payment or benefit described in this Plan constitutes “non-qualified
deferred compensation” under Section 409A of the Code, and to the extent that such payment or benefit is payable upon the Covered Executive’s termination of employment, then such payments or benefits shall be payable only upon the
Covered Executive’s “separation from service.” The determination of whether and when a separation from service has occurred shall be made in accordance with the presumptions set forth in Treasury Regulation Section 1.409A-1(h). 
 (d) All in-kind benefits provided and
expenses eligible for reimbursement under this Plan shall be provided by the Company or incurred by the Covered Executive during the time periods set forth in this Plan. All reimbursements shall be paid as soon as administratively practicable, but
in no event shall any reimbursement be paid after the last day of the taxable year following the taxable year in which the expense was incurred. The amount of in-kind benefits provided or reimbursable expenses
incurred in one taxable year shall not affect the in-kind benefits to be provided or the expenses eligible for reimbursement in any other taxable year (except for any lifetime or other aggregate limitation
applicable to medical expenses). Such right to reimbursement or in-kind benefits is not subject to liquidation or exchange for another benefit. 

(e) The Company makes no representation or warranty and shall have no liability to the Covered Executive or any other person if any provisions
of this Plan are determined to constitute deferred compensation subject to Section 409A of the Code but do not satisfy an exemption from, or the conditions of, such Section. 

  
 8 

 12. Notice and Date of Termination.  

(a) Notice of Termination. A termination of the Covered Executive’s employment shall be communicated by Notice of Termination from
the Company to the Covered Executive or vice versa in accordance with this Section 12. 
 (b) Notice to the Company. Any notices,
requests, demands, and other communications provided for by this Plan shall be sufficient if in writing and delivered in person or sent by registered or certified mail, postage prepaid, to a Covered Executive at the last address the Covered
Executive has filed in writing with the Company, or to the Company at the following physical or email address: 
 Pliant Therapeutics, Inc.

 Attention: Chief Human Resource Officer 

260 Littlefield Avenue 
 South San
Francisco, CA 94080 
 13. No Mitigation. The Covered Executive is not required to seek other employment or to attempt in any way to
reduce any amounts payable to the Covered Executive by the Company under this Plan. 
 14. Benefits and Burdens. This Plan shall inure
to the benefit of and be binding upon the Company and the Covered Executives, their respective successors, executors, administrators, heirs and permitted assigns. In the event of a Covered Executive’s death after a termination of employment but
prior to the completion by the Company of all payments due to him or her under this Plan, the Company shall continue such payments to the Covered Executive’s beneficiary designated in writing to the Company prior to his or her death (or to his
or her estate, if the Covered Executive fails to make such designation). 
 15. Enforceability. If any portion or provision of this
Plan shall to any extent be declared illegal or unenforceable by a court of competent jurisdiction, then the remainder of this Plan, or the application of such portion or provision in circumstances other than those as to which it is so declared
illegal or unenforceable, shall not be affected thereby, and each portion and provision of this Plan shall be valid and enforceable to the fullest extent permitted by law. 

16. Waiver. No waiver of any provision hereof shall be effective unless made in writing and signed by the waiving party. The failure of
any party to require the performance of any term or obligation of this Plan, or the waiver by any party of any breach of this Plan, shall not prevent any subsequent enforcement of such term or obligation or be deemed a waiver of any subsequent
breach. 

  
 9 

 17. Non-Duplication of Benefits and Effect on
Other Plans. Notwithstanding any other provision in the Plan to the contrary, the benefits provided hereunder shall be in lieu of any other severance payments and/or benefits provided by the Company, including any such payments and/or benefits
pursuant to an employment agreement or offer letter between the Company and the Covered Executive, other than as provided in Section 3(d) of the Company’s 2020 Stock Option and Incentive Plan, as amended from time to time; provided, that
in the event the Covered Executive is party to an agreement or other arrangement with the Company that provides greater benefits than set forth in this Plan, such employee shall be entitled to receive the payments or benefits under such other
agreement or arrangement and shall not be eligible to receive any payments or benefits under this Plan and the defined terms in the Plan shall supersede the corresponding defined terms or other similar terms in such other agreement or arrangement.

 18. No Contract of Employment. Nothing in this Plan shall be construed as giving any Covered Executive any right to be retained in
the employ of the Company or shall affect the terms and conditions of a Covered Executive’s employment with the Company. 
 19.
Amendment or Termination of Plan. The Company may amend or terminate this Plan at any time or from time to time, but no such action shall adversely affect the rights of any Covered Executive without the Covered Executive’s written
consent. 
 20. Governing Law. This Plan shall be construed under and be governed in all respects by the laws of the State of
Delaware, without giving effect to the conflict of laws principles. 
 21. Obligations of Successors. In addition to any obligations
imposed by law upon any successor to the Company, any successor (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of the business or assets of the Company shall expressly assume and agree to
perform this Plan in the same manner and to the same extent that the Company would be required to perform if no such succession had taken place. 

22. Effectiveness and Term. The Executive Severance Plan is effective as of     , 2020. 

  
 10 

 Exhibit A 

Tier 2 Executives 
  

			
	 Individual
	  	 Title

		
		  	Chief Financial Officer
		
		  	Chief Human Resource Officer
		
		  	Chief Business Officer
		
		  	Chief Medical Officer

  
 11EX-10.8

 Exhibit 10.8 

Pliant Therapeutics 

700 Saginaw Drive 

Suite 150 

Redwood City, CA 94063 
 Oct
7th, 2015 
 Bernard Coulie, MD, Ph.D. 
 BY EMAIL: 

Grimdestraat 23 
 B-3000
Leuven 
 BELGIUM 
 Re: Employment Offer Pliant Therapeutics

 Dear Bernard: 
 Pliant Therapeutics, Inc.
(“Pliant” or the “Company”) is pleased to confirm its offer to employ you. Your effective date of hire as a regular, full time employee (the “Start Date”) will be based on securing an O visa on your behalf. 

You will serve in the role of Chief Executive Officer. You will be responsible for building and leading the Company’s efforts and will report to the
Company’s Board of Directors (the “Board”). Responsibilities are expected to include, but may not limited to, the following: 
  

	 	•	 	 Work with the Board and senior management to formulate and communicate a compelling vision and strategic
direction for the company; evaluate alternative strategies; identify competitive issues; capitalize on platform technology and develop and implement operating plans to achieve objectives; 

 

	 	•	 	 Oversee all company activities to ensure Pliant meets its research, development, and financial milestones and all
other objectives including clinical, regulatory, and business development; 

  

	 	•	 	 Develop and maintain strategic partnerships with external companies, overseeing critical activities to ensure
research and development commitments and related projects are fulfilled; 

  

	 	•	 	 Serve as the primary spokesperson for company, establishing and communicating the company’s vision and
image, and enhancing its visibility among potential partners; 

  

	 	•	 	 Build additional organizational experience as needed within the management team. Work with the Board and the
senior management team to manage uncertainty while maintaining an entrepreneurial environment; 

  

	 	•	 	 Ensure that qualified research and development and managerial personnel are attracted and retained; manage
performance by providing feedback, teaching and development opportunities; 

 Bernard Coulie, M.D. Ph.D. 

Oct 7th, 2015 

 Page 
 2
 
  

	 	•	 	 Represent Pliant in scientific conferences, presentations, industry and investment groups; 

 

	 	•	 	 Build and maintain solid working relationships with our founders, scientific and clinical advisors, key opinion
leaders and investors; 

  

	 	•	 	 Foster an internal atmosphere that supports individual accountability, transparency, open communication and
respect to enable employees to focus on the Company’s mission. 

 Your salary will be paid at the rate of $375,000 per year, less
payroll deductions and withholdings. You will be paid semi-monthly in accordance with the Company’s usual payroll. It is expected that, when an annual bonus program is approved by the Board of Directors, you will be eligible for a target bonus
of 35% of your annual salary, based upon the achievement of corporate and individual goals, as determined by the Board. 
 In addition, the Company will
provide you with relocation assistance in the form of a sign-on bonus of $250,000. You will receive this payment during your first month of employment and it will be subject to customary deductions and
withholdings as required by law. Should you resign from your employment for any reason, other than for death or disability, within 24 months after receiving this payment, you will be obligated to return the gross amount of the payment to the Company
within 30 days after your last day of employment. 
 Pliant Therapeutics will reimburse you up to $20,000 annually for flights to/from San
Francisco/Belgium. 
 You will be eligible for standard Company benefits as they become implemented, including but not limited to health care insurance,
vacation, sick leave, holidays, 401(k), performance-based bonus program, and additional performance-based stock grants, subject to the terms and conditions of such plans. Until such time as a Company health care insurance plan is established, the
Company will reimburse you for premiums you pay for continuing benefits. Details about these benefit plans will be provided when they are available for your review. The Company may change compensation and benefits from time to time in its
discretion. 
 Subject to approval by the Board and after your “O” visa has been obtained under the Company’s equity incentive plan (the
“Plan”), you will be issued a restricted stock grant for 2,759,780 shares of the Company’s Common Stock (the “Restricted Stock”) with a purchase price per share equal to the fair market value as determined by the Board as of
the date of grant. The Restricted Stock will be subject to the terms and conditions of the Plan and your Restricted Stock agreement. Your grant agreement will include a four-year vesting schedule, under which 25 percent of your shares will vest
after twelve months of employment, with the remaining shares vesting monthly thereafter, until either your restricted stock is fully vested or your employment ends, whichever occurs first. 

As a Company employee, you will be expected to abide by Company rules and policies. As a condition of employment, you must sign and comply with the attached
Employee Confidential Information and Inventions Assignment Agreement, which prohibits unauthorized use or disclosure of Company proprietary information, among other obligations. 

 Bernard Coulie, M.D. Ph.D. 

Oct 7th, 2015 

 Page 
 3
 
  

 In your work for the Company, you will be expected not to use or disclose any confidential information,
including trade secrets, of any former employer or other person to whom you have an obligation of confidentiality. Rather, you will be expected to use only that information which is generally known and used by persons with training and experience
comparable to your own, which is common knowledge in the industry or otherwise legally in the public domain, or which is otherwise provided or developed by the Company. You agree that you will not bring onto Company premises any unpublished
documents or property belonging to any former employer or other person to whom you have an obligation of confidentiality. You hereby represent that you have disclosed to the Company any contract you have signed that may restrict your activities on
behalf of the Company. 
 Normal business hours are from 8:00 a.m. to 5:00 p.m., Monday through Friday. As an exempt salaried employee, you will be expected
to work additional hours as required by the nature of your work assignments. Your employment with the Company will be “at will.” You may terminate your employment with the Company at any time and for any reason whatsoever simply by
notifying the Company. Likewise, the Company may terminate your employment at any time, with or without cause or advance notice. Your employment at-will status can only be modified in a written agreement
signed by you and by an officer of the Company. 
 Notwithstanding the foregoing, if the Company terminates your employment without Cause (as defined
below), and other than for death or disability, then the Company will pay you severance (the “Severance”) in an amount equal to six (6) months of your base salary at the time of termination. Your eligibility to receive the Severance
will be conditioned upon your (i) signing and not revoking a release of any and all claims, in a form prescribed by the Company (the “Release”), and (ii) continued compliance with all legal and contractual obligations to the
Company. The Severance will be paid in a lump-sum, less deductions and withholdings, on the thirtieth (30th) day following your last day of employment,
provided the Release has become effective. “Cause” for termination of your employment shall exist if the Board determines, in its reasonable, good faith judgment that you engaged in any of the following behavior: (i) any act of
embezzlement, fraud, theft or misappropriation including without limitation with respect to any asset or property of the Company; (ii) gross negligence, willful misconduct or material neglect of duties or breach of fiduciary duty to the
Company; (iii) material failure to use good faith efforts to satisfactorily perform your duties (which failure continues after you have been given notice by the Company) or to follow the reasonable and lawful directions of the Board;
(iv) violation of federal or state securities laws as it relates to any of the Company’s securities; (v) material breach of an employment, consulting or other agreement with the Company that the Company and you have entered into or
any personnel policy of which you have been made aware after notice and opportunity to cure if such breach is curable; or (vi) conviction of a felony, or any crime involving moral turpitude. 

This offer is contingent upon satisfactory proof of your right to work in the United States. You agree to assist as needed and to complete any documentation
at the Company’s request to meet these conditions. 

 Bernard Coulie, M.D. Ph.D. 

Oct 7th, 2015 

 Page 
 4
 
  

 This letter, together with your Employee Confidential Information and Inventions Assignment Agreement, forms
the complete and exclusive statement of your employment agreement with the Company. It supersedes any other agreements or promises made to you by anyone, whether oral or written. Changes in your employment terms, other than those changes expressly
reserved to the Company’s discretion in this letter, require a written modification signed by an officer of Company. 
 Please sign and date this
letter, and the enclosed Employee Confidential Information and Inventions Assignment Agreement and return them to                      by close of
business on October 7th, 2015, if you wish to accept employment at the Company under the terms described above. 

We look forward to your favorable reply and to a productive and enjoyable work relationship. 

 

	
	Sincerely,
	
	/s/ Neil Exter
	 Neil Exter
 Chief Executive Officer, Pliant
Therapeutics, Inc.

  

	
	Accepted:
	
	/s/ Bernard Coulie
	Bernard Coulie, MD, Ph.D.
	
	October 12, 2015
	Date

 Attachment: [Employee Confidential Information and Inventions Assignment Agreement]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00309-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00309-of-00352.parquet"}]]